GLP-1 and birth control: what the labels say about the pill
Mounjaro's label advises backup contraception with the pill. Ozempic and Wegovy's do not. Here is what the data show, and what they leave out.
GLP-1 News & Updates
Evidence-based coverage of GLP-1 medications, telehealth, FDA updates, and clinical developments. Written by credentialed health professionals and medically reviewed.
GLP-1 medications and anesthesia: what 2026 fasting guidance says
Surgery advice has moved from stopping GLP-1s to adjusting fasting. See what the guidance says, what evidence backs it, and where experts differ.
Ozempic and vision loss: what the NAION research shows
What peer-reviewed studies, the FDA, and EMA actually say about semaglutide and NAION, a rare optic nerve stroke, versus lawsuit claims.
GLP-1 and gastroparesis: what the FDA label actually says
The FDA gastroparesis caution on GLP-1 labels isn't new for 2026. Here's the exact label language, the real study data, and what's unverified.
Medicare GLP-1 Bridge 2026: who qualifies for $50/month coverage
CMS's Medicare GLP-1 Bridge offers $50/month copays from July 2026 to Dec 2027. Here's who qualifies, who's excluded, and how the payment actually works.
Why GLP-1 drugs cause hair loss (and how to stop it)
Semaglutide and tirzepatide are linked to hair shedding in FDA and trial data. Here's what causes it, how long it lasts, and what actually helps.
Oral Wegovy pill vs. injection: cost, effectiveness, switching
The FDA-approved oral Wegovy pill vs. injections, compared on cost, GI side effects, and adherence, with the effectiveness data caveats you need.
Does stopping Ozempic or Wegovy cause weight regain?
Trial and real-world data on weight regain after stopping GLP-1 drugs, including how fast it happens and what it does to blood pressure and cholesterol.
Why GLP-1 drugs curb alcohol cravings: what the research shows
Trials show semaglutide reduces alcohol craving and heavy drinking. The effect is inconsistent across drugs, unapproved, and unproven long-term.
FDA Generic GLP-1 Approval 2026: What Changes for Consumers
Everything you need to know about the FDA's progress on generic GLP-1 approvals in 2026, including semaglutide, tirzepatide, pricing, and what it means for you.
Semaglutide Shortage Update: New Compounding Rules Take Effect June 2026
The FDA has announced new compounding regulations for GLP-1 medications. Here is what patients and telehealth providers need to know about sourcing compounded semaglutide safely.
Retatrutide Phase 3 Results: Triple Agonist Shows 24% Weight Loss at 48 Weeks
Eli Lilly has released Phase 3 clinical trial data for retatrutide, showing unprecedented weight loss results. Here is what the data means for patients and the GLP-1 market.
GLP-1 and Muscle Loss: New Research Shows Protein Protocol Can Preserve Lean Mass
A new clinical study demonstrates that a structured protein intake protocol combined with resistance exercise can significantly reduce muscle loss during GLP-1 therapy.
Subscribe to updates via our RSS feed. Never miss a clinical update or regulatory change.